Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 8/20 | 0.61 |
| ▸ | RAD52 | P43351 | 5/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.61 |
| ▸ | GLA | P06280 | 5/20 | 0.61 |
| ▸ | GAA | P10253 | 4/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | MITF | O75030 | 1/20 | 0.61 |
| ▸ | TTR | P02766 | 1/20 | 0.61 |
| ▸ | TOP2A | P11388 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | SLC2A1 | P11166 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.50 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 2/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15867121 | 0.91 | POLB (0.63) | POLBRAD52KDM4EGLAGAA | |
| SCHEMBL15867898 | 0.89 | POLB (0.59) | POLBRAD52KDM4EGLAGAA | |
| SCHEMBL14740714 | 0.85 | TOP2A (0.60) | POLBRAD52KDM4EGLAGAA | |
| SCHEMBL3360006 | 0.85 | POLB (0.67) | POLBRAD52KDM4EGLAGAA | |
| SCHEMBL1864822 | 0.85 | POLB (0.61) | POLBRAD52KDM4EGLAGAA | |
| SCHEMBL7880366 | 0.83 | POLB (0.78) | POLBRAD52KDM4EGLAGAA | |
| SCHEMBL15867118 | 0.81 | POLB (0.67) | POLBRAD52KDM4EGLAGAA | |
| SCHEMBL14740626 | 0.81 | POLB (0.81) | POLBRAD52KDM4EGLAGAA | |
| SCHEMBL557775 | 0.80 | POLB (0.65) | POLBRAD52KDM4EGLAGAA | |
| Trifluoroacetic Acid SCHEMBL7874384 | 0.79 | POLB (0.63) | POLBRAD52KDM4EGLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9090640-B2 | Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof | WAKE FOREST UNIVERSITY | 2015-07-28 | — | — | US | disclosed |
| US-9090640-B2 | Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof | WAKE FOREST UNIVERSITY | 2015-07-28 | — | — | US | disclosed |
| US-9090640-B2 | Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof | WAKE FOREST UNIVERSITY | 2015-07-28 | — | — | US | disclosed |
| US-20140193334-A1 | Targeted Delivery and Prodrug Designs for Platinum-Acridine Anti-Cancer Compounds and Methods Thereof | WAKE FOREST UNIVERSITY | 2014-07-10 | — | — | US | disclosed |
| US-20140193334-A1 | Targeted Delivery and Prodrug Designs for Platinum-Acridine Anti-Cancer Compounds and Methods Thereof | WAKE FOREST UNIVERSITY | 2014-07-10 | — | — | US | disclosed |
| US-20140193334-A1 | Targeted Delivery and Prodrug Designs for Platinum-Acridine Anti-Cancer Compounds and Methods Thereof | WAKE FOREST UNIVERSITY | 2014-07-10 | — | — | US | disclosed |
| WO-2013033430-A1 | TARGETED DELIVERY AND PRODRUG DESIGNS FOR PLATINUM-ACRIDINE ANTI-CANCER COMPOUNDS AND METHODS THEREOF | WAKE FOREST SCHOOL OF MEDICINE (US) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140193334-A1 | Targeted Delivery and Prodrug Designs for Platinum-Acridine Anti-Cancer Compounds and Methods Thereof | ERBB3, EGFR, ESR1 | POLB 4366/4885RAD52 2529/4885KDM4E 2722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.